CL2008001920A1 - Composicion farmaceutica que comprende un inhibidor de la pde 2, un agonista del receptor selectivo e2 y un portador; y uso en el tratamiento de fractura y/o defecto oseo (div. sol. 3179-04). - Google Patents
Composicion farmaceutica que comprende un inhibidor de la pde 2, un agonista del receptor selectivo e2 y un portador; y uso en el tratamiento de fractura y/o defecto oseo (div. sol. 3179-04).Info
- Publication number
- CL2008001920A1 CL2008001920A1 CL200801920A CL2008001920A CL2008001920A1 CL 2008001920 A1 CL2008001920 A1 CL 2008001920A1 CL 200801920 A CL200801920 A CL 200801920A CL 2008001920 A CL2008001920 A CL 2008001920A CL 2008001920 A1 CL2008001920 A1 CL 2008001920A1
- Authority
- CL
- Chile
- Prior art keywords
- oseo
- pde
- div
- sol
- fracture
- Prior art date
Links
- 229940121828 Phosphodiesterase 2 inhibitor Drugs 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 230000007547 defect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52999403P | 2003-12-16 | 2003-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008001920A1 true CL2008001920A1 (es) | 2008-10-17 |
Family
ID=34710150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200801920A CL2008001920A1 (es) | 2003-12-16 | 2008-06-27 | Composicion farmaceutica que comprende un inhibidor de la pde 2, un agonista del receptor selectivo e2 y un portador; y uso en el tratamiento de fractura y/o defecto oseo (div. sol. 3179-04). |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US20070135457A1 (es) |
| EP (1) | EP1697356B1 (es) |
| JP (1) | JP4073944B2 (es) |
| KR (1) | KR100816179B1 (es) |
| CN (1) | CN100439366C (es) |
| AP (1) | AP2006003632A0 (es) |
| AR (1) | AR046766A1 (es) |
| AT (1) | ATE387446T1 (es) |
| AU (1) | AU2004303609A1 (es) |
| BR (1) | BRPI0417663A (es) |
| CA (1) | CA2549510A1 (es) |
| CL (1) | CL2008001920A1 (es) |
| DE (1) | DE602004012154T2 (es) |
| DK (1) | DK1697356T3 (es) |
| EA (1) | EA010424B1 (es) |
| EC (1) | ECSP066643A (es) |
| ES (1) | ES2299888T3 (es) |
| GE (1) | GEP20094720B (es) |
| GT (1) | GT200400268A (es) |
| HN (1) | HN2004000538A (es) |
| HR (1) | HRP20080142T3 (es) |
| IL (1) | IL175813A0 (es) |
| IS (1) | IS8474A (es) |
| MA (1) | MA28270A1 (es) |
| MX (1) | MXPA06006777A (es) |
| NL (1) | NL1027787C2 (es) |
| NO (1) | NO20063231L (es) |
| PE (1) | PE20050681A1 (es) |
| PL (1) | PL1697356T3 (es) |
| PT (1) | PT1697356E (es) |
| RS (1) | RS50575B (es) |
| SI (1) | SI1697356T1 (es) |
| SV (1) | SV2005001979A (es) |
| TN (1) | TNSN06186A1 (es) |
| TW (1) | TWI291961B (es) |
| UA (1) | UA83091C2 (es) |
| UY (1) | UY28671A1 (es) |
| WO (1) | WO2005061497A1 (es) |
| ZA (1) | ZA200604970B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2633035C (en) * | 2005-12-15 | 2016-05-10 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
| WO2008035816A1 (fr) * | 2006-09-21 | 2008-03-27 | Toshiki Oguro | Promoteur de régénération des tissus durs |
| JP5472638B2 (ja) * | 2008-03-18 | 2014-04-16 | 日産化学工業株式会社 | １−（置換フェニル）−１−置換シリルエーテル、アルコールまたはケトンの製造方法および中間体 |
| WO2010062366A1 (en) * | 2008-10-31 | 2010-06-03 | Arginetix, Inc. | Compositions and methods of treating endothelial disorders |
| US8680116B2 (en) | 2009-07-22 | 2014-03-25 | Merck Sharp & Dohme Corp. | Quinolinone PDE2 inhibitors |
| US8440710B2 (en) | 2009-10-15 | 2013-05-14 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| US20140038989A1 (en) | 2011-04-20 | 2014-02-06 | Glaxo Group Limited | Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds |
| KR20150005936A (ko) | 2012-04-25 | 2015-01-15 | 다케다 야쿠힌 고교 가부시키가이샤 | 질소화 헤테로시클릭 화합물 |
| EP2873669A4 (en) | 2012-07-13 | 2015-11-25 | Takeda Pharmaceutical | HETEROCYCLIC COMPOUND |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| EP2975031A4 (en) | 2013-03-14 | 2017-04-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| ES2950424T3 (es) | 2013-07-03 | 2023-10-09 | Takeda Pharmaceuticals Co | Compuesto de amida |
| JP6427491B2 (ja) | 2013-07-03 | 2018-11-21 | 武田薬品工業株式会社 | 複素環化合物 |
| JPWO2015012328A1 (ja) * | 2013-07-24 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2015096651A1 (en) | 2013-12-23 | 2015-07-02 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as pde2 inhibitors |
| EP3091983B1 (en) | 2014-01-08 | 2019-10-02 | Intra-Cellular Therapies, Inc. | Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor |
| EP3174408B1 (en) * | 2014-08-01 | 2018-12-05 | Firmenich SA | Solid dispersion of amide flavor compounds |
| JP6608933B2 (ja) | 2014-12-06 | 2019-11-20 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| JP6608934B2 (ja) | 2014-12-06 | 2019-11-20 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| WO2016154081A1 (en) | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
| WO2016179059A1 (en) | 2015-05-05 | 2016-11-10 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as pde2 inhibitors |
| WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016192083A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| EP3313852B1 (en) * | 2015-06-25 | 2021-01-20 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| EP3156405A1 (en) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| GB201700814D0 (en) * | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| AU2018371216A1 (en) | 2017-11-23 | 2020-06-04 | Oslo University Hospital Hf | Treatment of tachycardia |
| CN109758458B (zh) * | 2019-03-05 | 2021-02-23 | 中国人民解放军陆军军医大学第二附属医院 | 抑制Crif1与PKA相互作用的化合物的应用 |
| US11648254B2 (en) | 2021-03-02 | 2023-05-16 | Kumquat Biosciences Inc. | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling |
| US11912708B2 (en) | 2022-04-20 | 2024-02-27 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2749344A (en) * | 1953-01-02 | 1956-06-05 | Burroughs Wellcome Co | Pyrimidine compounds |
| US2926166A (en) * | 1954-01-04 | 1960-02-23 | Burroughs Wellcome Co | Pyrido (2, 3-d) pyrimidine compounds and method of making |
| US3021332A (en) * | 1954-01-04 | 1962-02-13 | Burroughs Wellcome Co | Pyrido (2, 3-d) pyrimidine compounds and method of making |
| US2924599A (en) * | 1956-07-16 | 1960-02-09 | Anchor Chemical Company Ltd | Derivatives of 1:3:5-triazanaphthalene |
| US2937284A (en) * | 1958-05-01 | 1960-05-17 | Burroughs Wellcome Co | 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method |
| US3288792A (en) * | 1962-07-05 | 1966-11-29 | Burroughs Wellcome Co | Method of preparing 2, 4-diamino-6-alkylpyrido (2, 3-d) pyrimidines |
| DE3422824A1 (de) * | 1984-06-20 | 1986-01-02 | Celamerck Gmbh & Co Kg, 6507 Ingelheim | Neue herbizid wirksame sulfonylharnstoffe |
| US6194166B1 (en) * | 1993-05-24 | 2001-02-27 | Takara Shuzo Co., Ltd. | Gene regulating aureobasidin sensitivity |
| US5547954A (en) * | 1994-05-26 | 1996-08-20 | Fmc Corporation | 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides |
| US6262059B1 (en) * | 1995-06-07 | 2001-07-17 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with quinazoline derivatives |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
-
2004
- 2004-12-06 PT PT04801323T patent/PT1697356E/pt unknown
- 2004-12-06 GE GEAP20049461A patent/GEP20094720B/en unknown
- 2004-12-06 UA UAA200606683A patent/UA83091C2/ru unknown
- 2004-12-06 AT AT04801323T patent/ATE387446T1/de not_active IP Right Cessation
- 2004-12-06 CN CNB2004800376743A patent/CN100439366C/zh not_active Expired - Fee Related
- 2004-12-06 RS RSP-2008/0172A patent/RS50575B/sr unknown
- 2004-12-06 AU AU2004303609A patent/AU2004303609A1/en not_active Abandoned
- 2004-12-06 SI SI200430637T patent/SI1697356T1/sl unknown
- 2004-12-06 CA CA002549510A patent/CA2549510A1/en not_active Abandoned
- 2004-12-06 EP EP04801323A patent/EP1697356B1/en active Active
- 2004-12-06 WO PCT/IB2004/004013 patent/WO2005061497A1/en active Application Filing
- 2004-12-06 AP AP2006003632A patent/AP2006003632A0/xx unknown
- 2004-12-06 DE DE602004012154T patent/DE602004012154T2/de not_active Expired - Fee Related
- 2004-12-06 PL PL04801323T patent/PL1697356T3/pl unknown
- 2004-12-06 JP JP2006544574A patent/JP4073944B2/ja not_active Expired - Fee Related
- 2004-12-06 ES ES04801323T patent/ES2299888T3/es active Active
- 2004-12-06 KR KR1020067011800A patent/KR100816179B1/ko not_active IP Right Cessation
- 2004-12-06 DK DK04801323T patent/DK1697356T3/da active
- 2004-12-06 BR BRPI0417663-4A patent/BRPI0417663A/pt not_active IP Right Cessation
- 2004-12-06 MX MXPA06006777A patent/MXPA06006777A/es active IP Right Grant
- 2004-12-06 EA EA200600973A patent/EA010424B1/ru not_active IP Right Cessation
- 2004-12-06 US US10/595,766 patent/US20070135457A1/en not_active Abandoned
- 2004-12-15 UY UY28671A patent/UY28671A1/es not_active Application Discontinuation
- 2004-12-15 AR ARP040104668A patent/AR046766A1/es not_active Application Discontinuation
- 2004-12-15 GT GT200400268A patent/GT200400268A/es unknown
- 2004-12-15 TW TW093138972A patent/TWI291961B/zh active
- 2004-12-15 NL NL1027787A patent/NL1027787C2/nl not_active IP Right Cessation
- 2004-12-16 SV SV2004001979A patent/SV2005001979A/es not_active Application Discontinuation
- 2004-12-16 HN HN2004000538A patent/HN2004000538A/es unknown
-
2005
- 2005-01-03 PE PE2005000028A patent/PE20050681A1/es not_active Application Discontinuation
-
2006
- 2006-05-18 IS IS8474A patent/IS8474A/is unknown
- 2006-05-22 IL IL175813A patent/IL175813A0/en unknown
- 2006-06-15 EC EC2006006643A patent/ECSP066643A/es unknown
- 2006-06-15 ZA ZA200604970A patent/ZA200604970B/en unknown
- 2006-06-16 TN TNP2006000186A patent/TNSN06186A1/fr unknown
- 2006-06-16 MA MA29113A patent/MA28270A1/fr unknown
- 2006-07-11 NO NO20063231A patent/NO20063231L/no not_active Application Discontinuation
-
2008
- 2008-03-28 HR HR20080142T patent/HRP20080142T3/xx unknown
- 2008-06-27 CL CL200801920A patent/CL2008001920A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008001920A1 (es) | Composicion farmaceutica que comprende un inhibidor de la pde 2, un agonista del receptor selectivo e2 y un portador; y uso en el tratamiento de fractura y/o defecto oseo (div. sol. 3179-04). | |
| NO20052496D0 (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter. | |
| EE200300236A (et) | 1,2-difenüülasetidinoonid, nende kasutamine, ravim ja selle valmistamismeetod | |
| ATE460942T1 (de) | Exendine zur glucagon suppression | |
| ZA200502247B (en) | Selected CGRP antagonists, method for production and use thereof as medicament. | |
| NO20032797L (no) | Substituerte pyridoindoler som serotonin agonister og antagonister | |
| RS50660B (sr) | Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže | |
| DK1326630T3 (da) | Anvendelse af GLP-2-peptider | |
| CL2007002649A1 (es) | Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes. | |
| CL2004000788A1 (es) | Compuestos derivados de n-[2-oxo-6-(aril o heteroaril)azepan-3-il]-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxamida, antagonistas de los receptores cgrp; composicion farmaceutica; y uso del compuesto en el tratamiento del d | |
| CL2007002594A1 (es) | Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. . | |
| CL2004001293A1 (es) | Composicion farmaceutica que comprende compuestos antibacterianos como florfenicol, tiamfenicol, cloramfenicol en combinacion con al menos un portador seleccionado de triacetina, dimetilacetamida o una mezcla de ellas; y su uso en el tratamiento de u | |
| BRPI0312649A2 (pt) | compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos. | |
| AR058308A1 (es) | Fragmentos vip y metodos de uso de los mismos | |
| DE60312049D1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff | |
| BRPI0717369A2 (pt) | Composto, medicamento, composição farmacêutica que o contém e uso do composto. | |
| ES2190205T3 (es) | Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda. | |
| CL2007003198A1 (es) | Compuestos diarilicos opcionalmente nitrogenados, antagonistas de los receptores opioides; composicion farmaceutica; y uso en el tratamiento de la obesidad. | |
| AR028579A1 (es) | Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica | |
| UY28007A1 (es) | Tratamiento terapeutico | |
| CL2004000877A1 (es) | Combinacion farmaceutica que comprende 8a) melatonina y agonistas de la melatonina, y nicotina y agonistas receptores de nicotina; kit farmaceutico, y; uso en el tratamiento de insomnio, dificultades cognitivas y dificultades de memoria; kit farmaceu | |
| BR0208566B1 (pt) | Derivados de Beta-Carbolina, Seu Uso, e composição Farmacêutica | |
| ITRM20030363A0 (it) | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse. | |
| UY27753A1 (es) | Formulación farmacéutica que comprende melatonina. | |
| PA8618401A1 (es) | Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol |